Follow the treating anaesthetist's or surgeon's specific instructions as well as the relevant general guidance; clarify uncertainties before the procedure.

Disproportionate pain—greater than expected after injury or surgery and not relieved by analgesia—is a warning feature. Escalate neurovascular concerns promptly.

RACGP emphasises cardiovascular risk-factor management to improve overall survival and outcomes around future AAA repair; it is not a substitute for surveillance.

Symptomatic and ruptured aneurysms require emergency assessment and treatment; suspected rupture is not an outpatient surveillance problem.

The RACGP review reports no official population AAA screening programme in Australia; targeted screening decisions can be based on individual risk.

Targeted symptom and past history, function, alerting features for serious pathology, psychosocial factors and focused examination, including neurological examination when appropriate.

It supports assessment and preparation of people being considered for surgery, helping identify health issues and optimise preparation before anaesthesia.

Rapidly identify actual or potential life- or limb-threatening injury, initiate treatment and escalate using local trauma pathways.

The NSW protocol prompts for pre-hospital treatment and MIST handover, alongside mechanism, injury symptoms, relevant history, medicines and allergies.

AAA is generally asymptomatic and may be found incidentally on examination or imaging, or through targeted screening. Rupture is associated with high morbidity and mortality.

Deterioration may cause permanent deficit or limb loss. Serial assessment helps identify neurovascular compromise early and should be escalated when concerning.

Do not extend antimicrobials routinely after the procedure. Post-procedural antimicrobials are generally unnecessary unless infection is present; follow procedure-specific guidance.

Explain VTE, the risks and benefits of prevention, and involve patients in decisions about prevention during and after admission.

Continue ABCD reassessment, provide analgesia, explain the examination, uncover only as needed, and maintain warmth and privacy.

Women and trans and gender-diverse people aged 50–74 without breast symptoms are invited for a breast screen every two years.